Prostate cancer is a common neoplasm but conventional imaging methods such as CT and bone scan are often insensitive. A new class of PET agents have emerged to diagnose and manage prostate cancer.
The relevant literature on PET imaging agents for prostate cancer was reviewed.
This review shows a broad range of PET imaging agents, the most successful of which is prostate specific membrane antigen (PSMA) PET. Other agents either lack the sensitivity or specificity of PSMA PET.
Among the available PET agents for prostate cancer, PSMA PET has emerged as the leader. It is likely to have great impact on the diagnosis, staging and management of prostate cancer patients.
World journal of urology. 2020 Jul 15 [Epub ahead of print]
Esther Mena, Peter C Black, Soroush Rais-Bahrami, Michael Gorin, Mohamad Allaf, Peter Choyke
Molecular Imaging Program, National Cancer Institute, 10 Center Dr, Bldg 10, Room B3B69F, Bethesda, MD, 20892-1088, USA., University of British Columbia, Vancouver, BC, Canada., Department of Urology, University of Alabama at Birmingham, Birmingham, AL, USA., Department of Urology, Johns Hopkins University, Baltimore, MD, USA., Molecular Imaging Program, National Cancer Institute, 10 Center Dr, Bldg 10, Room B3B69F, Bethesda, MD, 20892-1088, USA. .